Safety and Efficacy of Molgramostim as an Adjunctive Therapy in Critically Ill Patients with Severe Sepsis

References

• Quesniaux V, Jones T. Granulocyte–macrophage colony stimulating factor. In: Thomson A, ed. The cytokine handbook, 3rd edn. London: Academic Press; 1998. p. 737–60.
   Google Scholar
• Burgess AW, Camarakis J, Metcalf D. Purification and properties of colony stimulating factor from mouse lung conditioned medium. J Biol Chem 1977; 252: 1998–2003.
   Google Scholar
• Wong GC, Witek JS, Temple PA. Human GM-CSF: molecular cloning of the complementary DNA and purring of the natural and recombinant proteins. Science 1985; 228: 810–5.
   Google Scholar
• Metcalf D, Nicola NA. The hemopoietic colony-stimulating factors: from biology to clinical applications. Cambridge: Cambridge University Press; 1995.
   Google Scholar
• Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant GM-CSF after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773–8.
   PubMed Web of Science ®Google Scholar
• Ganser A, Hoelzer D. Clinical use of hemopoietic growth factors in patients with myelodysplastic syndromes. Semin Hematol 1996; 33: 186–95.
   PubMed Web of Science ®Google Scholar
• Sprikkelman A, deWolf JT, Vellnga E. The application of hemopoietic growth factors in drug induced agranulocytosis: a review of 70 cases. Leukemia 1994; 8: 2031–6.
   Google Scholar
• Perno F, Ballestrero A, Ferrando F, et al. Replication of HIV in monocytes; GM-CSF potentiates viral replication yet enhances the anti-viral effect mediated by 3-azido-2,3′dideoxythymidine and other dideoxynucleosides of thymidine. J Exp Med 1989; 169: 933–51.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Siens S, Bergni M, Tarella G. GM-CSF to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580–4.
   Google Scholar
• Ganser A, Hoelzer D. Clinical use of hemopoietic growth factors in patients with myelodysplastic syndromes. Semin Hematol 1996; 33: 186–95.
   PubMed Web of Science ®Google Scholar
• Camitta BM, Storb R, Thomas ED. Aplastic anemia: pathogenesis, diagnosis, treatment and prognosis. N Engl J Med 1982; 306: 645–52, 712–8.
   Google Scholar
• Aviles A, Rosas A, Talavera A, et al. Use of GM-CSF in the treatment of infection and severe granulopenia. Cancer Res Therapy Control. 1994; 1: 1–5.
   Google Scholar
• Riikonen P, Saarinen UM, Makipernaa A, et al. Recombinant GM-CSF in the treatment of fever and neutropenia: a doubleblind placebo controlled study in children with malignancy. Pediatr Infect Dis 1994; 13: 197–200.
   Google Scholar
• Mayrdomo JI, Zorina T, Storkus WL, et al. Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995; i: 1297–302.
   Google Scholar
• Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med 1995; 21: 277–85.
   PubMed Web of Science ®Google Scholar
• Jaeschke, Smith CW. Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997; 61: 647–53.
   PubMed Web of Science ®Google Scholar
• Hack E, Thijs L. Role of inflammatory mediators in sepsis. In: Dhainaut J-F, Thijs L, Park G, eds. Septic shock, 1st edn. Philadelphia, PA: WB Saunders; 2000. p. 41–127.
   Google Scholar
• Demling RH. The modern version of adult respiratory distress syndrome. Annu Rev Med 1995; 46: 193–202.
   PubMed Web of Science ®Google Scholar
• Cebon J, Layton JE, Maher D, et al. Endogenous hemopoietic growth factors in neutropenia and infection. Br J Heaematol 1994; 86: 265–74.
   PubMed Web of Science ®Google Scholar
• Waring PM, Presneill JJ, Maher DW, et al. Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia. Clin Exp Immunol 1995; 102: 501–6.
   PubMed Web of Science ®Google Scholar
• Presneill JJ, Waring PM, Layton JE, et al. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality. Crit Care Med 2000; 28: 2344–54.
   PubMed Web of Science ®Google Scholar
• Tiegs G, Barsig J, Matiba B, Uhlig S, Wendel A. Potentiation by granulocyte macrophage colony stimulating factor of lipo- polysaccharide toxicity in mice. J Clin Invest 1994; 93: 2616–22.
   Google Scholar
• Randow F, Docke WD, Bundschuh D, Hartung T, Wendel A, Volk HD. In vitro prevention and reversal of LPS desensitization by INF-γ, IL-12, and GM-CSF. J Immunol 1997; 158: 2911–8.
   PubMed Web of Science ®Google Scholar
• Bundschuh D, Barsig J, Hartung T, Randow F, Docke WD, Volk HD, Wendel A. GM-CSF and interferon-gamma restore the systemic TNF alpha response to endotoxin in lipopolysaccharide desentitized mice. J Immunol 1997; 158: 2862–71.
   Google Scholar
• Members of the American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–74.
   Google Scholar
• Le Gall JR, Klar J, Lemenshow S, et al. The Logistic Organ Dysfunction System: a new way to assess organ dysfunction in intensive care unit. JAMA 1996; 276: 802–10.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 707–14.
   PubMed Web of Science ®Google Scholar
• Heumann D, Glauser M, Caladra T. Monocyte deactivation in septic shock. Curr Opin Infect Dis 1998; 11: 279–83.
   PubMed Web of Science ®Google Scholar
• Volk H-D, Reinke P, Docke W-D. Clinical aspects: from systemic inflammation to immunoparalysis. Chem Immunol 2000; 74: 162–77.
   PubMedGoogle Scholar
• Held TK, Cross AS. Role of hematopoietic factors in non-neu- tropenic infections and sepsis. Curr Opin Hematol 1999; 6: 176–83.
   PubMedGoogle Scholar
• Flohe S, Borgermann J, Dominguez FE, et al. Influence of GM-CSF on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Shock 1999; 12: 17–24.
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470–4.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Anaisse E, Gutterman J, Vathan-Rai S. Role of GM-CSF as adjuvant therapy for fungal infection in cancer patients. Clin Infect Dis 1993; 17: 705–7.
   PubMed Web of Science ®Google Scholar
• Jones TC. Use of GM-CSF in prevention and treatment of fungal infections. Eur J Cancer 1999; Suppl 3: S8–S10.
   Google Scholar
• Ruef C, Coleman DL. GM-CSF: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990; 12: 41–62.
   PubMedGoogle Scholar
• Molloy RG, Holzheimer R, Nestor M, Collins K, Mannick JA, Rodrick MI. GM-CSF modulates immune function and improves survival after experimental thermal injury. Br J Surg 1995; 82: 770–6.
   PubMed Web of Science ®Google Scholar
• Toda H, Murata A, Oka Y, et al. Effect of GM-CSF on sepsis induced organ injury in rats. Blood 1994; 83: 2893–8.
   PubMed Web of Science ®Google Scholar
• Pelt LJ, Huisman MV, Weening RS, Borne A, Roos D, Oers R. Single dose of GM-CSF induces systemic of IL-8 release and neutrophil activation in healthy volunteers. Blood 1996; 87: 5305–13.
   PubMed Web of Science ®Google Scholar
• Brissette WH, Baker DA, Stam EJ, Umlaud JP, Griffiths RJ. GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF-α. Cytokine 1995; 7: 291–5.
   PubMed Web of Science ®Google Scholar
• Zhang M, Tracey KJ. Tumor necrosis factor. In: Thomson A, ed. The cytokine handbook, 3rd edn. London: Academic Press; 1998. p. 517–48.
   Google Scholar